urbanhealth.strongbaltimore.net
Programs | Urban Health Institute
http://urbanhealth.strongbaltimore.net/programs
Engaging Communities, Improving Health. Bunting Neighborhood Leadership Program. Colorectal Cancer Screening Program. A Series on Understanding Racism and White Privilege. School of Education Seminar with Christina Berchini. Morning Dialogue with Christina Berchini. Noon Seminar with Christina Berchini. Morning Dialogue with Howard Ross. Noon Seminar with Howard Ross. Social Determinants of Health Symposium. Hopkins in Baltimore series. 1st Event - Johns Hopkins University. 3rd Event - School of Nursing.
urbanhealth.strongbaltimore.net
Funding Opportunities | Urban Health Institute
http://urbanhealth.strongbaltimore.net/funding-opportunities
Engaging Communities, Improving Health. Bunting Neighborhood Leadership Program. Colorectal Cancer Screening Program. A Series on Understanding Racism and White Privilege. School of Education Seminar with Christina Berchini. Morning Dialogue with Christina Berchini. Noon Seminar with Christina Berchini. Morning Dialogue with Howard Ross. Noon Seminar with Howard Ross. Social Determinants of Health Symposium. Hopkins in Baltimore series. 1st Event - Johns Hopkins University. 3rd Event - School of Nursing.
bwictu.jhu.edu
Our Sites | JHU Baltimore Washington India Clinical Trials
http://bwictu.jhu.edu/our-sites
JHU Baltimore Washington India Clinical Trials. Trials in Follow Up. CRS Leadership MTG Minutes. Network Protocol Progress Tracking List. The BWI-CTU integrates 3 highly productive Clinical Research Sites. Johns Hopkins University Adult CRS in Baltimore. Whitman Walker Health (WWH) CRS in Washington, DC. BJ Medical College (BJMC) CRS in Pune, India. To learn specific details about each site, follow the links above. A5288: MULTIOCTAVE, Management Using the Latest Technologies. A5225/HiFLAC is a Phase I/II...
bwictu.jhu.edu
People | JHU Baltimore Washington India Clinical Trials
http://bwictu.jhu.edu/about-us/people
JHU Baltimore Washington India Clinical Trials. Trials in Follow Up. CRS Leadership MTG Minutes. Network Protocol Progress Tracking List. Sheika Adams, RN. Allison Agwu MD, SCM. Associate Professor, Co-CRS leader. Research Assistant, ACTG Community Advisory Board Liaison, HPTN Community Educator. Adriana Andrade, MD, MPH. Assistant Professor of Medicine. Ashwin Balagopal, MD. Sagar Bhagwat, MBA, MS. Prof and Head, Dept of OB/GYN, and Protocol PI. Robert C. Bollinger, MD, MPH. Community and Outreach Team.
bwictu.jhu.edu
Publications | JHU Baltimore Washington India Clinical Trials
http://bwictu.jhu.edu/publications
JHU Baltimore Washington India Clinical Trials. Trials in Follow Up. CRS Leadership MTG Minutes. Network Protocol Progress Tracking List. Changes in Insulin Resistance After Initiation of Raltegravir or Protease. Dirajlal-Fargo, S, Moser C, Brown TT, Currier JS, Kelesidis T, Dube MP, Stein JH, Ribaudo HJ, McComsey GA. Open Forum Infectious Diseases, 2016, 3(3):ofw174. Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-,. J Infect Dis, 2016, 214(5):748-52. AIDS, 2016, 30(13):2091-7.
bwictu.jhu.edu
WWH (Washington DC) | JHU Baltimore Washington India Clinical Trials
http://bwictu.jhu.edu/our-sites/wwh-washington-dc
JHU Baltimore Washington India Clinical Trials. Trials in Follow Up. CRS Leadership MTG Minutes. Network Protocol Progress Tracking List. Translating research into clinical practice and bridging community efforts and scientific initiatives to combat HIV are at the center of WWH’s mission and values. The health center is thrilled to collaborate with JHU and BJMC as part of the ACTG and looks forward to making significant advancements in HIV and hepatitis research. 2014 – 2016 Johns Hopkins University.
bwictu.jhu.edu
CRS Leadership MTG Minutes | JHU Baltimore Washington India Clinical Trials
http://bwictu.jhu.edu/staff-only/crs-leadership-mtg-minutes
JHU Baltimore Washington India Clinical Trials. Trials in Follow Up. CRS Leadership MTG Minutes. Network Protocol Progress Tracking List. Please log in to view this page. A5274: REMEMBER, Reducing Early Mortality and Early. This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The. HPTN 069: A Phase II Randomized, Double-Blind, Study of the. A5273: Multicenter Study of Options for Second-Line. 2014 – 2016 Johns Hopkins University.
bwictu.jhu.edu
JHU (Baltimore) | JHU Baltimore Washington India Clinical Trials
http://bwictu.jhu.edu/our-sites/jhu-baltimore
JHU Baltimore Washington India Clinical Trials. Trials in Follow Up. CRS Leadership MTG Minutes. Network Protocol Progress Tracking List. The HIV Care Program serves as the most important resource for patient referrals to ACTG clinical trials, and is also an important referral source for HPTN trials. The Service is directed by Dr. Richard Moore, and was founded in 1983. The principal components are summarized below:. The HIV Inpatient Service:. Outpatient Clinical Research Unit:. The county program is op...
bwictu.jhu.edu
CTU Directory | JHU Baltimore Washington India Clinical Trials
http://bwictu.jhu.edu/staff-only/ctu-directory
JHU Baltimore Washington India Clinical Trials. Trials in Follow Up. CRS Leadership MTG Minutes. Network Protocol Progress Tracking List. Please log in to view this page. A5342: Evaluating the Safety, Tolerability, and Effect of a. The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody. A5274: REMEMBER, Reducing Early Mortality and Early. A5350: Effects of Visbiome Extra Strength on Gut Microbiome.
bwictu.jhu.edu
News | JHU Baltimore Washington India Clinical Trials
http://bwictu.jhu.edu/news
JHU Baltimore Washington India Clinical Trials. Trials in Follow Up. CRS Leadership MTG Minutes. Network Protocol Progress Tracking List. IMPAACT 2001 (DAIDS ID 12026): Evaluating the Pharmacokinetics,. Once-Weekly Rifapentine and Isoniazid in HIV-1-Infected and HIV-1-Uninfected Pregnant and Postpartum Women With Latent. V10 of IMPAACT 2001, a PK study of rifapentine and isoniazid in. CROI 2017 Highlighted ACTG Network Presentations. The Success of HIV Treatment Is Increasing the Risk of Drug-Resistance.
